German biotech company BioNTech and U.S. drugmaker Pfizer said they would begin a pivotal global study to evaluate their lead COVID-19 vaccine candidate.
Britain’s GSK said an injection of the company’s cabotegravir drug given every two months was found to be 65 percent more effective in preventing HIV infections than Gilead’s Truvada daily oral pills.
In a Phase III study, Genentech’s Tecentriq (atezolizumab) in combination with Celgene’s Abraxane followed by chemotherapy demonstrated a statistically significant and clinically meaningful improvement in treating patients with early triple-negative breast cancer.
AbbVie won a first-of-its-kind approval for a non-surgical treatment aimed at treating heavy menstrual bleeding due to uterine fibroids, a common non-cancerous tumor, in pre-menopausal women.
More than 17.6 million American adults (about 7.5 percent) experience allergic rhinitis (also called hay fever or seasonal allergies). Many different substances (called allergens) can trigger allergic rhinitis, such as tree or grass pollen, and each person has their own set of problematic allergens.
Companies from across the globe provide updates on their business and pipeline progress.
Netherlands-based Kiadis Pharma is discontinuing Phase III development of lead T-cell asset ATIR101 and laying off half of the company’s staff, seven months after acquiring CytoSen.
Foamix Pharmaceuticals is merging with Menlo Therapeutics to become a biopharma company focusing on dermatology.
Halozyme Therapeutics is restructuring after halting development of a metastatic pancreatic cancer drug that failed to demonstrate an improvement in overall survival in a Phase III trial.
After multiple failures to develop therapeutics for Alzheimer’s disease, Biogen’s Michael D. Ehlers resigned from his role as head of research and development.